ALMR (ALMR) Stock Price & Analysis
ALMR (ALMR) rose 4.79% to USD 20.13 as of June 10, 2026 at 11:03 UTC, according to Nexqual real-time market data.
ALMR last closed at USD 19.21; the session ranged USD 19.31–20.39 on volume of 137,940 shares. Market capitalization is $1.40B, with a 52-week range of USD 18.85–27.2 (NMS). Source: Nexqual, June 10, 2026 at 11:03 UTC.
Key Statistics (as of June 10, 2026 at 11:03 UTC)
| Price | USD 20.13 |
|---|---|
| Change | ▲ 4.79% (up) |
| Previous Close | USD 19.21 |
| Open | USD 19.36 |
| Day Range | USD 19.31 – 20.39 |
| 52-Week Range | USD 18.85 – 27.2 |
| Volume | 137,940 shares |
| Market Cap | $1.40B |
| Exchange | NMS |
Technical Analysis (ALMR)
Nexqual's technical model rates ALMR "SELL" based on 1 bullish and 3 bearish signals across 36 daily candles, as of June 10, 2026 at 11:03 UTC.
| Overall Signal | SELL |
|---|---|
| RSI (14) | 38.76 (neutral) |
| MACD | -1.07 (negative) |
Analyst Ratings (ALMR)
Wall Street analysts rate ALMR "Buy" based on 5 analysts, with a mean price target of USD 30 (range USD 27–35), per Nexqual as of June 10, 2026 at 11:03 UTC.
| Consensus Rating | Buy |
|---|---|
| Analyst Count | 5 |
| Mean Target | USD 30 |
| High Target | USD 35 |
| Low Target | USD 27 |
| Buy / Hold / Sell | 4 / 1 / 0 |
Earnings (ALMR)
| Next Earnings Date | 2026-08-06 |
|---|---|
| EPS Estimate | USD -0.32 |
| Revenue Estimate | $25.94M |
Source: Nexqual, June 10, 2026 at 11:03 UTC.
Financials & Fundamentals (ALMR)
| Total Revenue | $87.16M |
|---|---|
| Revenue Growth (YoY) | +98.90% |
| Gross Margin | +57.11% |
| Operating Margin | -47.42% |
| Profit Margin | -49.89% |
| Debt / Equity | 185.42 |
| Current Ratio | 5.88 |
| Total Cash | $64.59M |
| Total Debt | $105.55M |
Source: Nexqual, June 10, 2026 at 11:03 UTC.
Financial Health Score (ALMR)
Nexqual rates ALMR's overall financial health "Mixed" across five dimensions, as of June 10, 2026 at 11:03 UTC.
| Growth | Strong — Revenue +99% YoY (latest Q) |
|---|---|
| Profitability | Weak — Not yet profitable — scaling phase |
| Balance Sheet | Weak — $65M cash vs $106M debt |
| Cash Flow | Weak — Operating cash flow -$61M |
| Efficiency | Mixed — No data |
Ownership (ALMR)
| Insider Ownership | +26.67% |
|---|---|
| Institutional Ownership | +28.31% |
| Shares Outstanding | 69.31M |
| Float | 40.31M |
| Short % of Float | +4.14% |
Source: Nexqual, June 10, 2026 at 11:03 UTC.
Leadership (ALMR)
ALMR is led by Yuling Luo (age 61), Co-Founder, Chairman & CEO, per Nexqual as of June 10, 2026 at 11:03 UTC.
| Co-Founder, Chairman & CEO | Yuling Luo (age 61) |
|---|---|
| Co-Founder, COO & Director | Shiping Chen (age 62) |
| Chief Financial Officer | Justin J. McAnear (age 49) |
| President | Timothy Ogden White (age 57) |
| Chief Technology Officer | Xiao-Jun Ma |
Major Backers & Investors (ALMR)
Notable institutional backers of ALMR include Fidelity, ARK Invest, according to Nexqual as of June 10, 2026 at 11:03 UTC.
Active Investors
| Investor | Stake |
|---|---|
| Fidelity | 1.12% |
| ARK Invest | 0.78% |
Source: Nexqual, June 10, 2026 at 11:03 UTC.
Peers & Related Stocks
| Symbol | Name | Price | Change |
|---|---|---|---|
| KLRA | Kailera Therapeutics, Inc. | USD 19.64 | ▲ 1.39% |
| EIKN | Eikon Therapeutics, Inc. | USD 8.77 | ▼ 2.12% |
| GENB | Generate Biomedicines, Inc. | USD 13.19 | ▲ 2.49% |
| AVLN | Avalyn Pharma Inc. | USD 28.67 | ▲ 5.95% |
| COAG | Hemab Therapeutics Holdings, In | USD 27 | ▲ 6.72% |
Data source: Nexqual — real-time market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: June 10, 2026 at 11:03 UTC. This page is informational and not investment advice.